HC Wainwright Has Negative Forecast for Clene Q3 Earnings

Clene Inc. (NASDAQ:CLNN) – Equities research analysts at HC Wainwright lowered their Q3 2026 EPS estimates for Clene in a report released on Friday, August 14th. HC Wainwright analyst J. Pantginis now anticipates that the company will earn ($0.48) per share for the quarter, down from their previous forecast of ($0.46). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Clene’s current full-year earnings is ($1.58) per share. HC Wainwright also issued estimates for Clene’s Q4 2026 earnings at ($0.41) EPS and FY2026 earnings at ($2.17) EPS.

Clene (NASDAQ:CLNN) last issued its quarterly earnings data on Friday, August 14th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.71). The firm had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.06 million.

Other equities research analysts have also issued reports about the stock. Roth Capital reiterated a “buy” rating on shares of Clene in a research note on Thursday, May 14th. Weiss Ratings upgraded shares of Clene from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $23.00 price objective on shares of Clene in a report on Monday, May 4th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Clene has an average rating of “Moderate Buy” and an average price target of $33.25.

Clene Trading Up 1.4%

Shares of Clene stock opened at $4.20 on Tuesday. The company has a fifty day simple moving average of $5.58 and a 200-day simple moving average of $5.63. The stock has a market cap of $53.68 million, a price-to-earnings ratio of -1.20 and a beta of 0.96. Clene has a 12-month low of $3.64 and a 12-month high of $13.50.

Institutional Trading of Clene

Large investors have recently bought and sold shares of the business. Jane Street Group LLC acquired a new stake in shares of Clene during the second quarter worth about $47,000. State Street Corp increased its position in Clene by 138.4% in the 4th quarter. State Street Corp now owns 29,801 shares of the company’s stock valued at $175,000 after acquiring an additional 17,300 shares during the period. PEAK6 LLC purchased a new stake in Clene during the 4th quarter valued at approximately $294,000. Geode Capital Management LLC raised its stake in Clene by 8.0% during the 4th quarter. Geode Capital Management LLC now owns 82,079 shares of the company’s stock valued at $482,000 after acquiring an additional 6,090 shares during the last quarter. Finally, Scoggin Management LP lifted its position in Clene by 42.7% during the 2nd quarter. Scoggin Management LP now owns 142,750 shares of the company’s stock worth $558,000 after acquiring an additional 42,750 shares during the period. Institutional investors and hedge funds own 23.28% of the company’s stock.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).